Radiopharm Theranostics (ASX:RAD) EBIT: A$-38.17 Mil (TTM As of Jun. 2025)


What is Radiopharm Theranostics EBIT?

Radiopharm Theranostics ASX:RAD -5.00% EBIT is A$-38.17 Mil as of Jun. 2025. The stock has 5 warning signs investors should review.

Radiopharm Theranostics's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2025 was A$-18.37 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2025 was A$-38.17 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Radiopharm Theranostics's annualized ROC % for the quarter that ended in Jun. 2025 was -55.92%. Radiopharm Theranostics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2025 was -66,796.36%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Radiopharm Theranostics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2025 was -274.69%.

Radiopharm Theranostics  (ASX:RAD) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Radiopharm Theranostics's annualized ROC % for the quarter that ended in Jun. 2025 is calculated as:

ROC % (Q: Jun. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2024 ) + Invested Capital (Q: Jun. 2025 ))/ count )
=-29.672 * ( 1 - 0% )/( (53.91 + 52.22)/ 2 )
=-29.672/53.065
=-55.92 %

where

Invested Capital(Q: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=92.452 - 7.335 - ( 36.437 - max(0, 13.146 - 44.353+36.437))
=53.91

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=86.482 - 9.341 - ( 29.117 - max(0, 14.933 - 39.854+29.117))
=52.22

Note: The Operating Income data used here is two times the semi-annual (Jun. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Radiopharm Theranostics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2024  Q: Jun. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-36.738/( ( (0.057 + max(-6.847, 0)) + (0.053 + max(-14.596, 0)) )/ 2 )
=-36.738/( ( 0.057 + 0.053 )/ 2 )
=-36.738/0.055
=-66,796.36 %

where Working Capital is:

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(4.634 + 0 + 1.665) - (7.335 + 3.159 + 2.652)
=-6.847

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.337) - (9.341 + 1.721 + 3.871)
=-14.596

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Radiopharm Theranostics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2025 )
=-38.174/13.897
=-274.69 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Radiopharm Theranostics EBIT Related Terms

Radiopharm Theranostics EBIT Historical Data

* Premium members only.

The historical data trend for Radiopharm Theranostics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Radiopharm Theranostics EBIT Chart

Radiopharm Theranostics Annual Data
Trend Jun22 Jun23 Jun24 Jun25
EBIT
-20.95 -34.49 -47.21 -38.17

Radiopharm Theranostics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
EBIT Get a 7-Day Free Trial -22.48 -24.69 -22.52 -19.81 -18.37

ASX:RAD vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Radiopharm Theranostics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Radiopharm Theranostics EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Radiopharm Theranostics's EV-to-EBIT falls into.


Radiopharm Theranostics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-38.17 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of A$-38.17 Mil mean?
Radiopharm Theranostics (ASX:RAD) has a EBIT of A$-38.17 Mil as of Jun. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Radiopharm Theranostics.
Is Radiopharm Theranostics' EBIT too high?
Radiopharm Theranostics' current EBIT is A$-38.17 Mil.
How does Radiopharm Theranostics' EBIT compare to VRTX and REGN?
Radiopharm Theranostics' EBIT of A$-38.17 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Radiopharm Theranostics. Radiopharm Theranostics's current EBIT is A$-38.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radiopharm Theranostics stock overvalued right now?
Radiopharm Theranostics (ASX:RAD) has a current EBIT of A$-38.17 Mil. The current EBIT is A$-38.17 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Radiopharm Theranostics (ASX:RAD), the current EBIT is A$-38.17 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Radiopharm Theranostics Business Description

Other Exchanges RADX:USA
Address 62 Lygon Street, Suite 1, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.